Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + cisplatin concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma
ChiCTR1900025137Phase 4Not yet recruiting
- Sponsor
- Nanyang Central Hospital
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Nanyang Central Hospital. Primary endpoint: Overall survival time. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900025137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025137.